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A new apoptosis inhibitor is described from vaccinia virus, camelpox virus, and eukaryotic cells. The inhibitor is a
hydrophobic, multiple transmembrane protein that is resident in the Golgi and is named GAAP (Golgi anti-apoptotic
protein). Stable expression of both viral GAAP (v-GAAP) and human GAAP (h-GAAP), which is expressed in all human
tissues tested, inhibited apoptosis induced by intrinsic and extrinsic apoptotic stimuli. Conversely, knockout of h-GAAP
by siRNA induced cell death by apoptosis. v-GAAP and h-GAAP display overlapping functions as shown by the ability of
v-GAAP to complement for the loss of h-GAAP. Lastly, deletion of the v-GAAP gene from vaccinia virus did not affect
virus replication in cell culture, but affected virus virulence in a murine infection model. This study identifies a new
regulator of cell death that is highly conserved in evolution from plants to insects, amphibians, mammals, and
poxviruses.
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Introduction
Cell death is the result of either necrosis or apoptosis.
Necrosis is the outcome of severe and acute injury, whereas
apoptosis is an evolutionarily conserved, strictly regulated,
energy-dependent process of cell suicide responsible for the
ordered removal of superﬂuous, aged, or damaged cells,
including virus-infected cells [1]. The signals that trigger
apoptosis can be either extrinsic, and are sensed by death
receptors at the cell surface, or intrinsic following perturba-
tion of intracellular homeostasis, and are sensed by cellular
organelles that initiate cell death [2]. The mitochondrion is
the best known organelle regulating apoptosis, but the
endoplasmic reticulum (ER), lysosomes, nucleus, and Golgi
apparatus can all transmit stress signals to mitochondria, and
thus contribute to the induction of apoptosis [3–5].
Poxviruses are a family of large DNA viruses that replicate
in the cytoplasm [6]. The Orthopoxvirus genus is the most
extensively characterised genus of the Chordopoxvirinae [7]
and includes variola virus, the cause of smallpox, vaccinia
virus (VACV), the vaccine used to eradicate smallpox, and
camelpox virus (CMLV), which is closely related genetically to
variola virus [8]. The orthopoxviruses have genomes of
approximately 200 kilobase pairs and encode about 200
proteins [9]. Proteins encoded in the terminal regions of the
genome are mostly non-essential for virus replication but
affect virus virulence, host range, or the host responses to
infection. This group of proteins is numerous and includes
those that are secreted from the infected cell and bind
complement factors, interferons, cytokines, and chemokines
[10]. Alternatively, poxvirus immunomodulatory proteins
may be intracellular and interfere with signalling pathways
regulating cellular gene expression or apoptosis. Several
poxvirus proteins that inhibit apoptosis have been described
(for review, see [11]).
This study describes the identiﬁcation and characterisation
of a new poxvirus anti-apoptotic protein that is located in the
Golgi and is called viral Golgi anti-apoptotic protein (v-
GAAP). v-GAAP is non-essential for virus replication in cell
culture but affects virus virulence in a murine model of
infection. Strikingly, v-GAAP shows very high conservation
with a hitherto uncharacterised human protein (h-GAAP)
that is expressed in all human tissues tested, is essential for
cell viability, is anti-apoptotic, and is conserved in plants,
insects, amphibia, and mammals.
Results
Identification of GAAPs
CMLV gene 6L encodes a 237–amino acid (aa) protein with a
putative molecular mass of 26.5 kDa [8]. Database searches
revealed a striking similarity to a human protein (73% identity,
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h-GAAP) of unknown function that is present in public
databases under different names (e.g., z-protein, CGI-119, and
S1R protein). BLAST searches with h-GAAP identiﬁed closely
related, uncharacterised proteins in orangutan (96% identity),
dog (89% identity), mouse (84% identity), rat (84% identity),
Xenopus laevis (69% identity), and zebraﬁsh (65% identity). In
addition, there are related proteins of similar size predicted to
be encoded by Arabidopsis thaliana (38% identity) and Drosophila
melanogaster (34% identity) (Figure 1A).
Comparison of the sequence of all putative GAAPs showed
that, evolutionarily, GAAPs are extremely well conserved in
length (235–239 aa) and sequence identity. The close
relationship between GAAPs is supported further by their
conserved hydrophobicity proﬁle, which predicted a six or
seven transmembrane topology (Figure 1B and unpublished
data). The PFAM program [12] assigned the human and viral
GAAPs to the protein family UPF0005, whose members are
predicted to contain six or seven transmembrane domains
[13]. Two characterised UPF0005 family members show
similarity to GAAPs. Bax inhibitor-1, which protects cells
against ER stress, shares 28% identity (45% similarity) [14,15],
and lifeguard, which protects cells from Fas-mediated cell
death in the brain and other tissues, shares 34% identity
(51% similarity) [16].
Collectively, these data suggest that GAAPs have an
important and evolutionarily conserved function, possibly
in regulating apoptosis.
v-GAAP Is an Early Protein That Is Non-Essential for Virus
Replication and Localises to the Golgi
To examine the kinetics of v-GAAP protein expression, cells
were infected with CMLV in the presence or absence of
cytosine arabinoside (AraC), an inhibitor of DNA replication
and late gene expression. Reverse transcription (RT)–PCR
detected v-GAAP messenger RNA (mRNA) from 2 h post
infection (p.i.) onward and at 22 h p.i. in the presence of AraC.
In contrast, the CMLV late gene 110L, a counterpart of VACV
geneD8L [8,17], was only transcribed late during infection and
not in the presence of AraC (Figure 2A, left panel).
There is no established small animal model for studying the
contribution of speciﬁc genes to CMLV pathogenesis, so to
investigate the role of v-GAAP in virus virulence, we searched
other orthopoxviruses for orthologues of CMLV 6L. Bio-
informatic analysis of poxvirus genomes (http://www.poxvirus.
org) showed that the majority of orthopoxviruses do not
encode an orthologue of CMLV gene 6L, but an exception
was VACV Lister [18]. PCR ampliﬁcation of genomic DNA of
VACV strains Lister, USSR, and Evans using primers for
CMVL 6L yielded a 714–base pair (bp) fragment, the same
length as the CMVL 6L gene (unpublished data). DNA
sequencing conﬁrmed that these viruses encoded proteins
of 237 aa with 94%–95% identity with CMVL 6L.
To study the role of the viral protein, a set of VACV strain
Evans viruses (v-GAAP WT) were constructed in which the v-
GAAP gene was deleted (v-DGAAP) and re-inserted (v-GAAP
Rev) into the deletion mutant. We also constructed a virus in
which v-GAAP contained a C-terminal hemagglutinin (HA)
tag (vGAAP RevHA). PCR and Southern blot analysis
conﬁrmed that the genomic structures of all viruses were as
predicted. Comparisons of the growth of the recombinant
viruses in cell culture showed there were no differences in
plaque phenotype or yield of intracellular virus (unpublished
data). Immunoblotting of extracts from v-GAAP RevHA–
infected cells with anti-HA antibody (Ab) detected v-GAAP as
a 23-kDa protein that was present early and throughout
infection (Figure 2A, right panel). In contrast, VACV protein
A36 was expressed only late during infection as reported
previously [19]. These analyses showed that the kinetics of
expression of the CMLV and VACV v-GAAP genes were
indistinguishable.
To study the intracellular location of GAAPs, an Ab was
raised against a GAAP peptide, SSIEDDFNYGSSV (h-GAAP aa
11–23 and v-GAAP aa 10–22). Cells were infected with v-GAAP
WT, v-DGAAP, and v-GAAP Rev and ﬁxed for immunoﬂuor-
escence analysis 3, 6, or 24 h p.i. (Figure 2B, left subpanels;
unpublished data). v-GAAP co-localised with the Golgi marker
GM130 at each time point. Note that under these conditions,
endogenous h-GAAP was not detected due to its lower level of
expression (Figure 2B, middle left subpanel). In addition, very
late post-infection (24 h) v-GAAP was also detected in the
nuclear membrane and the ER (unpublished data). The a-
GAAP antibody also recognised v-GAAP as a 23-kDa protein
in extracts of cells infected with v-GAAP WT and v-GAAP Rev
but not v-DGAAP (Figure 2B, right panel).
Therefore, v-GAAP is expressed early in VACV infection,
localises to the Golgi, and is dispensable for VACV growth in
cell culture.
Figure 1. GAAPs Are Evolutionarily Conserved
(A) CLUSTALW [47] alignment of h-GAAP and v-GAAP with related proteins from other species: VACV strain Evans, CMLV strain CM-S, human, orangutan,
dog, mouse, X. laevis, zebrafish, A. thaliana, and D. melanogaster. Identical residues are shown in black, and residues conserved in six to eight or nine out
of ten sequences are in light or dark grey, respectively. Horizontal bars show predicted transmembrane domains (I–VII) based on the Kyte–Doolittle
hydropathy model. An asterisk denotes a block of 20 aa.
(B) Hydrophobicity profiles of human, VACV, and A. thaliana GAAPs according to Kyte and Doolittle, plotted using the program WinPep [48]. Putative
transmembrane domains (I–VII) are outlined.
doi:10.1371/journal.ppat.0030017.g001
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Author Summary
Apoptosis is a conserved and strictly regulated process of cell
suicide that, among other things, can remove virus-infected cells. In
turn, many viruses, including poxviruses, have evolved strategies to
block apoptosis to keep cells alive until virus replication is
completed. Here, a novel viral anti-apoptotic protein from vaccinia
virus and camelpox virus, viral Golgi anti-apoptotic protein (v-GAAP),
and its human counterpart, h-GAAP, are described. Evolutionarily,
GAAPs are extremely well conserved with closely related proteins in
plants, insects, amphibia, and mammals, the viral and human
counterparts sharing a striking 73% sequence identity. GAAPs are
resident in the Golgi and inhibit apoptosis induced by a wide range
of apoptotic stimuli. Knockout of h-GAAP, which is expressed in
every tissue tested, induced cell death by apoptosis. The close
relationship between the viral and the human proteins was
confirmed in that v-GAAP could complement for the loss of h-
GAAP and promote cell survival. Deletion of the v-GAAP gene from
vaccinia virus affected virus virulence. Thus, this study identifies a
new regulator of cell death that is highly conserved in evolution and
has been hijacked by poxviruses. These data support a role for the
Golgi complex in sensing pro-apoptotic stimuli.
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Figure 2. Human and Viral GAAPs Are Golgi Proteins
(A) Time of v-GAAP expression during infection. Semi-quantitative RT-PCR (30 cycles) analysis of CMLV-infected TK143 cells for presence of mRNA for v-
GAAP and CMLV gene 110L (equivalent to VACV gene D8L) (left panel). The right panel shows an immunoblot analysis of v-GAAP RevHA–infected
TK143 cells for expression of v-GAAP and the late VACV protein A36 using a-HA and a-A36 mAbs, respectively. m, mock.
(B) v-GAAP localises to the Golgi. HeLa cells were infected with v-GAAP WT, v-DGAAP, and v-GAAP Rev for 6 h and stained for v-GAAP using anti-GAAP
Ab and for Golgi using anti-GM130 Ab. Scale bars, 20 lm. The right panel shows an immunoblot analysis of v-GAAP mutant viruses 16 h p.i. using the a-
GAAP Ab. The black arrow (left panel) indicates the GAAP protein.
(C) Tissue expression profile of h-GAAP. The 714-bp h-GAAP gene (35 cycles, top panel) or 983-bp glyceraldehyde-3-phosphate dehydrogenase (G3PDH)
gene fragment (30 cycles, bottom panel) were amplified by PCR from human cDNA master panels and analyzed by agarose gel electrophoresis.
intestine, small intestine; PBL, peripheral blood leukocyte; sk. muscle, skeletal muscles.
(D) h-GAAP localises to the Golgi. HeLa cells were stained for endogenous h-GAAP and Golgi marker GM130 using anti-GAAP and anti-GM130–specific
Abs. Scale bars, 20 lm. Pre-immune serum was used as a control (right panel).
doi:10.1371/journal.ppat.0030017.g002
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h-GAAP Is Expressed in All Tissues Tested and Localises to
the Golgi
GAAPs are extremely well conserved evolutionarily (Figure
1). To investigate whether h-GAAP was expressed in different
human tissue, complementary DNA (cDNA) from 16 human
tissues obtained from multiple disease-free individuals was
used for PCR analysis of h-GAAP gene expression. This
showed that h-GAAP is expressed in all human tissue
examined (Figure 2C). Next, the a-GAAP Ab was used to
study the location of h-GAAP by immunoﬂuorescence; this
demonstrated that endogenous h-GAAP co-localised with the
Golgi marker GM130 in HeLa, SiHa, and BGMK cells (Figure
2D and unpublished data). Therefore, h-GAAP is widely
expressed in human tissues and, like v-GAAP, is a Golgi
protein.
Expression of GAAPs
To investigate the function of GAAPs, we expressed h-
GAAP or v-GAAP bearing a C-terminal HA tag in stable cell
lines (U2OS-v-GAAP and U2OS-h-GAAP) (Figure 3A and 3B)
Figure 3. Location of GAAPs
(A) U2OS-neo (top row), U2OS-v-GAAP (middle row), or U2OS-h-GAAP (lower row) cells were stained using an anti-HA mAb together with an a-GM130
Ab. All primary Abs were detected with secondary Abs conjugated to fluorescein isothiocyanate or tetramethylrhodamine isothiocyanate. Scale bars, 20
lm. The right panel shows an immunoblot analysis of U2OS stable cell lines using an a-HA mAb.
(B) Top left panel: Cryo-immunoelectron microscopy was used to label the v-GAAP HA-tagged protein in U2OS v-GAAP cells with anti-HA mAb
(Covance, diluted 1/10), followed by rabbit anti-mouse (Cappel) and 6-nm protein-A Au (scale bars 100 nm, top left panel). Golgi stack morphology was
compared in the different cell lines by conventional thin sections of Epon-embedded samples and was examined by electron microscopy in U2OS-neo
(top right panel), US-OS-v-GAAP (lower left panel), and U2OS h-GAAP (lower right panel). Scale bars, 200 nm.
(C) HeLa cells were transfected with pCI-h-GAAPHA or pCI-v-GAAPHA and fixed 4 h post transfection. GAAPs were detected using an a-HA mAb, and
cells were co-stained with the Golgi marker a-GM130. Scale bars, 20 lm.
doi:10.1371/journal.ppat.0030017.g003
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and in cells transiently by transfection (Figure 3C). In U2OS
cells stably expressing h-GAAP or v-GAAP, the expression
levels varied among individual cells, but, in all cases, GAAPs
co-localised with the Golgi markers GM130 (Figure 3A) and
giantin (unpublished data). This subcellular distribution was
the same as for v-GAAP during VACV infection (Figure 2). In
cells with higher expression levels, h-GAAP and v-GAAP were
also seen in a reticular network characteristic of the ER (co-
staining with protein disulﬁde isomerase, unpublished data).
A similar distribution was seen in transfected cells (Figure
3C): early after transfection, viral GAAPs localized to only the
Golgi (Figure 3C), but later, as their concentration increased,
they were also present in the ER (unpublished data). To
examine if GAAP expression was polarised to either the cis or
trans Golgi cisternae, U2OS-v-GAAP and U2OS-h-GAAP cells
were analysed by immunoelectron microscopy using protein-
A gold (Figure 3B) or immunocytochemistry (unpublished
data). v-GAAP was expressed throughout the stacks of the
Golgi complex (Figure 3B, upper left panel), and similar
results were obtained for h-GAAP (unpublished data). In
U2OS-v-GAAP, and to a lesser extent in U2OS-h-GAAP cells,
the Golgi complex appeared more dispersed than in parental
U2OS cells (Figure 3A), but electron microscopy showed
retention of Golgi stack morphology (Figure 3B). Moreover,
transfection of a plasmid expressing vesicular stomatitis virus
glycoprotein fused to green ﬂuorescent protein (VSV-GFP)
into these cells showed that protein trafﬁcking to the cell
surface was normal (Figure S1).
Therefore, both human and viral GAAPs are distributed
throughout the Golgi stacks, and when they are overex-
pressed, glycoprotein trafﬁcking to the plasma membrane is
normal.
h-GAAP Is Necessary for Cell Survival
To study h-GAAP function, three small interfering RNAs
(GAAP siRNAs 1–3) were designed to down-regulate h-GAAP
expression. RT-PCR showed that GAAP siRNAs 1 and 3 down-
regulated h-GAAP mRNA substantially by 36 h post trans-
fection, whereas GAAP siRNA2 and a control siRNA against
GFP did not (Figure 4A). Strikingly, transfection of HeLa cells
withGAAP siRNAs 1 and 3, but not GAAP siRNA2, induced cell
death by 56 h post transfection (Figure 4B). Next, we measured
the mitochondrial membrane potential using the membrane
potential–sensitive dye tetramethylrhodamine ethyl ester
(TMRE) 56 h after transfection of HeLa cells with GAAP
siRNAs 1–3. Consistent with cell morphology changes, HeLa
cells transfected with GAAP siRNAs 1 and 3 showed a
decreased uptake of the TMRE compared with that of mock-
transfected cells and cells transfected with GAAP siRNA2 and
GFP-siRNA (Figures 4C and S2). In addition, immunoblotting
showed cleavage of poly (adenosine diphosphate–ribose)
polymerase (PARP) in HeLa cells transfected with h-GAAP
siRNA1, but not in mock- or GFP-siRNA–transfected cells
(Figure 4D). Immunoﬂuorescence using U2OS-h-GAAP cells
conﬁrmed that h-GAAP protein expression was reduced to
background by 36 h after transfectionwithGAAP siRNAs 1 and
3, but not with siRNA2 or GFP-siRNA (Figure 4E). Immuno-
blotting demonstrated that h-GAAP protein expression was
undetectable 56 h after transfection with GAAP siRNAs 1 and
3, but not with siRNA2 and GFP-siRNA (Figure 4F). These data
indicate that h-GAAP is necessary for cell survival.
GAAPs Inhibit Apoptosis Triggered by the Intrinsic
Pathway
The similarity of GAAPs to anti-apoptotic proteins (life-
guard and Bax inhibitor-1) and the observation that knock
down of h-GAAP expression induced apoptosis, suggest that
GAAPs regulate apoptosis. Accordingly, we tested whether h-
GAAP and v-GAAP affected the induction of apoptosis by ﬁve
different pro-apoptotic stimuli that act through the intrinsic
pathway (Bax, staurosporine, cisplatin, doxorubicin, and C2-
ceramide) [20–24]. To test whether GAAPs modulate Bax-
induced apoptosis, Saos-2 cells were transfected with an
expression plasmid for Bax alone, or together with pCI-v-
GAAP (CMLV or VACV Evans) or pCI-h-GAAP and the cell
surface marker CD20. Figure 5A (left panel) shows represen-
tative DNA proﬁles of transfected (CD20-positive) cells 36 h
post transfection. Quantiﬁcation of sub-G1 cell populations
(M1) showed that expression of Bax alone caused ;25%
apoptosis among the transfected cell population, and this
number was reduced by half when v-GAAPs (CMLV or VACV
Evans) or h-GAAP were co-expressed with Bax (Figure 5A,
right panel). Immunoblot analysis demonstrated that expres-
sion of GAAPs did not interfere with Bax expression levels
(Figure 5B, right panel).
Apoptosis was then induced using staurosporine, a broad-
spectrum kinase inhibitor. Staurosporine (3 lM) induced
apoptosis in only 28% and 46% U2OS-v-GAAP and U2OS-h-
GAAP cells, respectively, when compared to U2OS-neo cells
(Figure 5B). To assess whether h-GAAP could also suppress
cell death induced via p53 activation, U2OS-neo, U2OS-v-
GAAP, and U2OS-h-GAAP cells were treated with cisplatin or
doxorubicin. Treatment of cells with cisplatin (10 lg/ml)
resulted in apoptosis in 38% and 48% of U2OS-v-GAAP and
U2OS-h-GAAP cells, respectively, when compared to U2OS-
neo cells (Figure 5B). Similar results were obtained after
doxorubicin treatment (unpublished data).
Thus, GAAPs inhibit apoptosis in response to Bax,
staurosporine, cisplatin, and doxorubicin. However, the most
striking anti-apoptotic activity of GAAPs was against C2-
ceramide (10 lM). This treatment induced apoptosis in 35%
of U2OS-neo cells, whereas apoptosis in U2OS v-GAAP and
U2OS-h-GAAP cells was inhibited completely and remained
similar to untreated cells (Figure 5D).
GAAPs Regulate Cell Susceptibility to Apoptosis Triggered
by the Extrinsic Pathway
To investigate whether h-GAAP and v-GAAP could inhibit
apoptosis triggered via the extrinsic pathway, U2OS-neo,
U2OS-v-GAAP, or U2OS-h-GAAP cells were treated with
either anti-human Fas Ab (CH11) or human tumour necrosis
factor (TNF)–a. Treatment with anti-Fas Ab and cyclo-
heximide (CHX) caused apoptosis in 22% of U2OS-neo cells
(Figure 6A) compared to 10% in U2OS-h-GAAP cells and 6%
in U2OS-v-GAAP cells. Similarly, treatment with human
TNF-a and CHX caused apoptosis in 19% of control cells, but
only in 11% of U2OS-h-GAAP cells and 5% of U2OS-v-GAAP
cells. Consistently (n ¼ 3), compared to control cells treated
with anti-Fas antibody or TNF-a (designated as 100%),
apoptosis was reduced to 46.3% and 62.5% in U2OS h-GAAP
cells and to 28.2% and 29.6% in U2-OS v-GAAP cells,
respectively (Figure 6B).
To deﬁne the site of action of h-GAAP, we treated U2OS-
neo and U2OS-h-GAAP cells with TNF-a and CHX and
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examined cleavage of caspase-8. There was no gross differ-
ence in proteolytic cleavage of caspase-8 into its active p43/
p41 and p18 fragments between both cell lines after 2, 4, and
6 h (Figure 6C). In contrast, from 2 h onwards, cleavage of the
PARP was reduced in U2OS-h-GAAP compared to that in
U2OS-neo cells (Figure 6D). Similar results were obtained
after Fas and CHX treatment (unpublished data) and when
comparing U2OS-neo with U2OS-v-GAAP cells (unpublished
data). Thus, overexpression of human and viral GAAPs
provides partial protection against apoptosis triggered by
the extrinsic pathway, and this inhibition takes place down-
stream of caspase-8 cleavage.
v-GAAP Can Complement for Loss of h-GAAP
Human and viral GAAP RNA sequences share 77%
nucleotide identity, so the use of speciﬁc siRNAs enables
differential degradation of viral and/or human mRNA. GAAP
siRNA1 was designed to down-regulate h-GAAP and v-GAAP,
whereas GAAP siRNAs 2 and 3 were speciﬁc for h-GAAP.
Accordingly, we tested GAAP siRNAs 1–3 for their ability to
down-regulate v-GAAP in the U2OS human cell line that we
had engineered to stably express v-GAAP, U2OS-v-GAAP.
Immunoﬂuorescence analysis showed that 36 h post trans-
fection, GAAP siRNA1 down-regulated h-GAAP and v-GAAP,
whereas siRNAs 2 and 3 did not affect v-GAAP expression,
and siRNA2 affected neither h-GAAP nor v-GAAP (Figure
7A). Just as in HeLa cells (Figure 4B), U2OS-h-GAAP cells
transfected with h-GAAP siRNAs 1 and 3, but not siRNA2,
died by 48 h post transfection (Figure 7B, lower panels). In
contrast, U2OS-v-GAAP cells, in which endogenous h-GAAP
was down-regulated but v-GAAP was still expressed (siRNA3),
remained healthy (Figure 7B, upper panels). Consistent with
the cell morphology and the result of HeLa cell transfection
(Figure 4B), U2OS-h-GAAP cells transfected with GAAP
siRNAs 1 and 3 and U2OS-v-GAAP transfected with GAAP
siRNA1 showed reduced uptake of TMRE (unpublished data).
Therefore, downregulation of h-GAAP causes cell death by
apoptosis, and v-GAAP can complement for loss of h-GAAP
to promote cell survival.
v-GAAP Is a Virulence Factor
The role of v-GAAP protein in virus virulence was
investigated using a murine intranasal model [25,26]. Mice
were infected intranasally with 107 plaque-forming units (pfu)
of v-GAAP WT, v-DGAAP, or v-GAAP Rev, and the weight
change and signs of illness (rufﬂed fur, arched backs, reduced
mobility, or evidence of pneumonia [27]) were assessed daily.
In repeated experiments (n ¼ 5), there was no signiﬁcant
difference in weight loss when comparing mice infected with
v-DGAAP to those infected with v-GAAP WT and v-GAAP
Rev (Figure 8A). However, a signiﬁcant increase in signs of
illness (p  0.05, Student’s t-test) was observed in v-DGAAP
compared to both control groups on days 5 and 8 p.i. (Figure
8B). Similar results were obtained after infection of mice with
33 106 pfu (unpublished data): mice infected with v-DGAAP
showed increased signs of illness compared to mice infected
with v-GAAP WT and v-GAAP Rev.
To assess why infection with v-DGAAP resulted in more
severe signs of illness, the virus titres in lungs were
determined at different times p.i. Each virus replicated well
in lung tissue to reach titres .106 pfu/gm of tissue by 3 d p.i.,
and there were no statistically signiﬁcant differences between
virus titres of the different groups detected on this day or
later (unpublished data). Next, the inﬂammatory inﬁltrate in
the lungs of infected mice was examined. In repeated
experiments (n ¼ 3), at days 6 and 8 p.i., signiﬁcantly more
cells were recovered from bronchoalveolar lavages (BALs) of
mice infected with v-DGAAP than from mice infected with v-
GAAP WT and v-GAAP Rev (Figure 8C; p  0.01, Student’s t-
test). As reported previously after VACV infection [28], there
was a low level of cell recruitment to the lungs of infected
animals early after infection, and this increased to a
maximum at 10 d p.i. with v-GAAP WT and v-GAAP Rev,
and at day 8 with v-DGAAP (unpublished data).
These results show that loss of v-GAAP altered the
virulence of VACV in an intranasal murine model of
infection.
Discussion
A new regulator of apoptosis is described that is encoded
by VACV, CMLV, and many other eukaryotes. This protein is
called Golgi-anti-apoptotic protein because of its function
and subcellular location. Overexpression of h-GAAP or v-
GAAP rendered cells resistant to induction of apoptosis,
while knock down of expression of the human gene by siRNA
caused cells to die by apoptosis. Deletion of v-GAAP from
VACV did not affect virus replication in cell culture, but
affected virulence in a murine model of infection. v-GAAP
therefore represents a new virus-encoded apoptosis inhibitor.
v-GAAP is remarkable in that it is very closely related to a
previously uncharacterised human protein (h-GAAP) that is
conserved in a wide range of eukaryotes, is expressed in all 16
human tissues tested, and is essential for cell viability.
VACV and other poxviruses express a wide range of
proteins that interfere with aspects of the host response to
infection (for reviews see [10,29]). These proteins may act
inside or outside the cell, and most of them target the innate
Figure 4. Downregulation of h-GAAP Causes Cell Death by Appotosis
HeLa cells (A–D) or U2OS-h-GAAP cells (E and F) were transfected with siRNA oligos directed to h-GAAP (siRNAs 1–3) or GFP (GFP-siRNA) for 36 h (A and
E), or 56 h (B–D and F).
(A) mRNA level of h-GAAP in HeLa cells was assessed by semi-quantitative RT-PCR (35 cycles) using h-GAAP- or actin-specific primers, respectively.RT
indicates negative control.
(B) HeLa cell morphology was recorded using a Zeiss Axiovert 200M Live Imaging System with an AxioCam HRc CCD. Images shown are representative
of at least three independent experiments.
(C) HeLa cells were loaded with the fluorescent dye TMRE and loss of the inner mitochondrial membrane potential was assessed by TMRE fluorescence
two-color flow cytometry. The graph shows the percentage of cells with decreased TMRE uptake compared to mock-transfected cells. Data are mean
percentages from at least three independent experiments (one of which is shown in Figure S2). *, p , 0.05; ** p , 0.005.
(D) HeLa cells were treated with GFP-siRNA or h-GAAP siRNA1 or were mock-treated and assessed for cleavage of PARP by immunoblotting.
(E and F) h-GAAP protein expression in U2OS-h-GAAP cells was assessed by immunofluorescence (E) or immunoblotting (F) using an a-HA mAb. In (E),
the upper row of panels show the fluorescent images, and the bottom row shows a merged image of the top panels and an image of the same cells
taken by differential interference contrast microscopy. Data are representative of three independent experiments. Scale bars, 20 lm.
doi:10.1371/journal.ppat.0030017.g004
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Figure 5. h-GAAP Decreases Cell Susceptibility to Intrinsic Apoptosis Pathways
(A) Transient assay of Bax-induced apoptosis. Saos-2 cells were transfected with different plasmids as indicated, and representative flow cytometry
profiles of CD20-positive cells are shown. The bar graph represents the percentage of sub-G1 cells (labeled M1 in the left panel). Data are mean
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response to infection. Among the intracellular regulators of
the innate response, a subset block the induction of
apoptosis, so that virus replication can be completed before
the cells dies. Apoptosis regulators from VACV and other
poxviruses have been reviewed recently [11] and include
proteins that inhibit caspase activity, or are present at the
mitochondrial membrane. v-GAAP is another example of an
intracellular apoptosis inhibitor, but it has three striking
differences from the ones discovered previously.
First, v-GAAP (and h-GAAP) is present in the Golgi, a
compartment that until recently was not thought to have an
important role in the regulation of apoptosis [5,30]. This
observation supports recent evidence that the Golgi has a role
in the regulation of apoptosis. Other poxvirus proteins that
affect induction of apoptosis are located either at mitochon-
dria or are in the cytosol.
Second, v-GAAP is very closely related to a human protein
that shows remarkable conservation throughout eukaryotes.
The virus and human protein have 73% aa identity, a similar
hydropathy proﬁle, and a very similar length. Moreover, the
genomes of many eukaryotes (plants, insects, amphibia, and
mammals) encode a closely related protein. For instance, the
human and Arabidopsis GAAPs share 38% aa identity and
differ in length by only 4 aa. Hitherto, the function of the
protein we have called GAAP had not been determined in any
species, although the human gene was one of several reported
to be up-regulated in some breast tumours [31]. Data
presented here provide the ﬁrst characterisation to our
knowledge of the human protein, and demonstrate that this
protein is essential for cell viability and that cells die by
apoptosis in its absence. In addition, it is shown that the viral
protein can complement the essential function served by h-
GAAP. Other immunoregulatory proteins from poxviruses
either have no orthologues outside poxviruses or have a much
lower amino acid identity with cellular counterparts. For
instance, the interleukin-1b receptor [32], interferon-c
receptor [33], and 3b-hydroxy-steroid dehydrogenase [34]
from VACV share 33%, 25%, and 44% aa identity with their
human orthologues, respectively. Therefore, compared to
other orthopoxvirus immunomodulators, v-GAAP shows by
far the greatest amino acid similarity with its mammalian
counterpart. The close relationship of the GAAPs in VACV
and mammals suggests that either the gene has been captured
from the host more recently in evolution, or that functional
constraints have restricted its divergence after acquisition.
Third, v-GAAP (and h-GAAP) inhibits apoptosis induced by
Figure 6. h-GAAP Decreases Cell Susceptibility to Extrinsic Apoptosis Pathways
(A) U2OS-neo, U2OS-v-GAAP, or U2OS-h-GAAP cells were treated with 10 lg/ml of CHX alone or together with 500 ng/ml of anti-Fas Ab or 10 ng/ml of
TNF-a. The bar graph represents the percentage of apoptotic cells (6 1 SD) after 24 h.
(B) Relative inhibition of Fas and TNF-a–induced apoptosis in U2OS-neo (designated as 100%), U2OS-v-GAAP, and U2OS-h-GAAP cells. Data are mean
percentages (6 1 SD) from at least three independent experiments. Statistically significant differences are shown.
(C and D) After 2, 4, or 6 h incubation with TNF-a and cycloheximide, proteolytic cleavage of caspase-8 into p43/p41 and p18 fragments (C) and PARP
(D) were assessed by immunoblotting.
doi:10.1371/journal.ppat.0030017.g006
percentages from at least two independent experiments. Protein expression was detected by immunoblotting using a-Bax or a-HA antibodies,
respectively.
(B–D) U2OS-neo, U2OS-v-GAAP, or U2OS-h-GAAP cells were mock-treated or treated with 3 lM staurosporine for 6 h (B), 10 lg/ml cisplatin for 24 h (C),
or 10 lM C2-ceramide for 36 h (D), and apoptosis was assessed as above. The graphs show the relative percentage of apoptosis induced by
staurosporine (B) or cisplatin (C). Data are mean percentages (6 1 standard deviation [SD]) from at least two independent experiments done in
triplicate.
(D) After 24 h treatment with C2-ceramide, the cell morphology was recorded as for Figure 3B. The graphs show the percentage of sub-G1 cells induced
by C2-ceramide. Data are mean percentages (6 1 SD) from at least two independent experiments done in triplicate. Statistically significant differences
are shown.
doi:10.1371/journal.ppat.0030017.g005
PLoS Pathogens | www.plospathogens.org February 2007 | Volume 3 | Issue 2 | e170255
Golgi Anti-Apoptotic Protein
an unusually broad range of pro-apoptotic stimuli from both
the extrinsic and intrinsic pathways. Instrinsic pro-apoptotic
stimuli inhibited by GAAPs include bax, staurosporine,
doxorybicin, cisplatin, and ceramide. Extrinsic stimuli in-
hibited include Fas and TNF. The mechanism by which
GAAPs inhibit apoptosis remains to be determined. The
ability of GAAPs to inhibit cell death induced by various
instrinsic apoptotic stimuli suggests strongly that it acts at a
step in the mitochondrial pathway. The ﬁnding that h-GAAP
suppressed TNF-induced apoptosis at a step downstream of
caspase-8 activation is consistent with this idea.
In summary, a new regulator of apoptosis has been
Figure 7. v-GAAP Complements for Loss of h-GAAP
(A) U2OS-v-GAAP or U2OS-h-GAAP cells were transfected with siRNA oligonucleotides directed against h-GAAP (siRNAs 1–3) or v-GAAP (siRNA1) for 36
h. v-GAAP and h-GAAP expression was assessed by immunofluorescence using an a-HA mAb, followed by secondary Ab conjugated to FITC. The upper
and third rows of panels show the fluorescent images, and the second and bottom rows show merged images of the fluorescent panel (immediately
above) and an image of the same cells taken by differential interference contrast microscopy. Images shown are representative for at least three
independent experiments. Scale bars, 20 lm.
(B) Cell morphology of U2OS-h-GAAP or U2OS-v-GAAP cells 56 h after transfection with GAAP siRNAs 1–3 was assessed as for Figure 4B.
doi:10.1371/journal.ppat.0030017.g007
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discovered by the study of poxviruses. The protein, called v-
GAAP in VACV and h-GAAP in Homo sapiens, is highly
conserved in eukaryotes, and is another example of a host
gene acquired during virus evolution to combat the host
response to infection. The human protein is essential for cell
viability, and in its absence cells die by apoptosis. Both human
and viral GAAPs inhibit an unusually wide range of pro-
apoptotic stimuli. The viral protein affects virus virulence and
can also substitute for the h-GAAP to maintain cell viability.
Materials and Methods
Cells and viruses. Monkey BS-C-1 and human HeLa, TK143,
U2OS (osteosarcoma, p53 wild-type), and Saos2 (osteosarcoma, p53-
null) cells were grown in Dublbecco’s modiﬁed Eagle’s medium
(Gibco, http://www.invitrogen.com) with 10% (v/v) heat-inactivated
fetal bovine serum. The source of VACV strain Evans and CMLV
strain CM-S were described previously [8,27].
GAAPs antiserum. The peptide sequence SSIEDDFNYGSSV (h-
GAAP aa 11–23 and v-GAAP aa 10–22) was conjugated to keyhole
limpet hemocyanin via a C-terminal cysteine residue and used to
immunize rabbits (Sigma-Genosys, http://www.sigmaaldrich.com/
Brands/Sigma_Genosys.html). The speciﬁcity of the Abwas conﬁrmed
by immunoﬂuorescence using U2OS cells stably expressing HA-tagged
human or viral GAAPs showing that the signal obtained is identical to
the signal given by the anti-HA monoclonal antibody (mAb).
Tissue expression proﬁle of h-GAAP. The presence of h-GAAP
mRNA in different tissues was analyzed using Human Multiple Tissue
cDNA panels I and II (Clontech, http://www.clontech.com) and semi-
quantitative RT-PCR with Platinum PCR SuperMix (Invitrogen, http://
www.invitrogen.com). cDNAs were ampliﬁed with h-GAAP speciﬁc
primers. To deﬁne the optimal number of PCR cycles for linear
ampliﬁcation, an aliquot from each of the samples was removed at 20
cycles, and thereafter at every ﬁfth additional cycle.
Cloning of human and viral GAAPs. CMLV strain CM-S and VACV
strain Evans genomic DNA were used for PCR ampliﬁcation of the v-
GAAPgeneswith the inﬂuenzavirusHAepitopeYPYDVPDYAencoded
at the 39 end. These fragments were cloned into the plasmid pCDNA3.1
(Invitrogen). Oligonucleotides were identical for both viral proteins: v-
GAAP exp1 (59-GCCCCGAATTCCGCCGCCATGGCAATGCCG) and
v-GAAPexp2-HA (59-GCCCCTCGAGTAAagcgtaatcaggcacgtcgtaaggg-
taTTTCTTATTAGATACTTCCAAAAGC). Bold, underlined, or lower
case nucleotides represent the translation initiation and termination
codons, restriction sites, and HA tag, respectively.
For the h-GAAP gene, total RNA was isolated from HeLa cells and
h-GAAP cDNA was cloned by RT-PCR into pCDNA3.1 using the
ThermoScript RT-PCR System (Invitrogen) and oligonucleotides h-
GAAPexp1 (59-GCCCCGAATTCTGCCATCATGGCTGACCCCG) and
h-GAAPexp2HA (59- GCCCCTCGAGTTAagcgtaatcaggcacgtcgtaaggg-
taCTTTTTATTAACTGCTTCCAGAAACC). Bold, underlined, or low-
er case nucleotides represent the translation initiation and
termination codons, restriction sites, and HA tag, respectively. The
ﬁdelity of all DNA sequences was conﬁrmed by sequencing. For
transient transfection experiments, human and viral GAAPs cDNA
were subcloned into pCI (Promega, http://www.promega.com).
Construction of GAAP mutant viruses. A VACV mutant lacking
the GAAP gene was constructed using a plasmid assembled by
splicing by overlap extension (SOE)-PCR [35]. Two DNA fragments
were ampliﬁed representing either the 59 (307 bp) or 39 (462 bp)
ﬂanking regions of the GAAP gene, using oligonucleotides DGAAP-1
(59-GCCCCGTCGACGATGTGATAAATACAGCGATACC) and
DGAAP-2 (59-CCAATCCATGTTTTGACCTATATATTAATACTC)
or oligonucleotides DGAAP-3 (59-TAATATATAGGTCAAAACATG-
Figure 8. v-GAAP Is an Immunomodulator
Groups of four BALB/c mice aged between 6 and 8 wk were mock-
infected with PBS () or infected with 107 pfu of v-GAAP WT (¤), v-
DGAAP (&), or v-GAAP Rev (m).
(A) Mice were weighed daily, and results are the mean percentage
weight change of each group 6 standard error of the mean (SEM)
compared with the weight on the day of infection.
(B) Animals from (A) were monitored daily for signs of illness, which was
scored as described [27]. Data are expressed as the mean 6 SEM. p-
Values were determined by using Student’s t-test and indicate mean
weight loss (A) or mean signs of illness. *, p-values of mice infected with
v-DGAAP that were significantly different from those of mice infected
with v-GAAP WT and v-GAAP Rev (B).
(C) Mice infected intranasally with 107 pfu of v-GAAP WT, v-DGAAP, or v-
GAAP Rev were sacrificed at various days p.i. as indicated. BAL cells were
recovered and counted. Columns represent the mean cell yield per
mouse 6 SEM. Those marked with an asterisk indicate mean cell
numbers recovered with v-DGAAP that were significantly different (p ,
0.05) from those recovered from v-GAAP WT and v-GAAP Rev (three
independent experiments with groups of four to five mice).
doi:10.1371/journal.ppat.0030017.g008
PLoS Pathogens | www.plospathogens.org February 2007 | Volume 3 | Issue 2 | e170257
Golgi Anti-Apoptotic Protein
GATTGGAAAC) and DGAAP-4 (CGGGGAATTCGTAGCGTGG-
CAATGACAG), respectively. Annealing regions are shown in bold
and restriction sites are underlined. The 59 and 39 GAAP deletion
fragments were joined by SOE-PCR using oligonucleotides DGAAP-
1 and DGAAP-4, and the product was cloned into pSJH7 [36],
forming pSJH7-DGAAP.
To make a revertant virus, a wild-type copy of the GAAP gene was
ampliﬁed by PCR using oligonucleotides DGAAP-1 and DGAAP-4
and VACV Evans genomic DNA as template. This product was
cloned into pSJH7, forming pSJH7-GAAP-Rev. For the construction
of a VACV expressing v-GAAP with a C-terminal HA tag, plasmid
pSJH7-GAAPRevHA was constructed by SOE-PCR as for pSJH7-
DGAAP using oligonucleotides DGAAP-1, DGAAP-2RevHA (59-
AGCGTAATCAGGCACGTCGTAAGGGTATTTCTTATTAGA-
TACTTCCAAAAGC), DGAAP-3RevHA (59- TACGACGTGCCTGAT-
TACGCTTAAAGTTTAAAATAGAATTAATAAAAACATATAGG),
and DGAAP-4 and VACV genomic DNA as template.
Recombinant viruses were constructed by transient dominant
selection [6] using the Escherichia coli guanine xanthine phosphor-
ibosyltransferase (Ecogpt) gene as the selectable marker [37]. Brieﬂy,
pSJH7-DGAAP was transfected into CV-1 cells that were infected with
VACV Evans, and a deletion mutant (v-DGAAP) and a wild-type
control virus (v-GAAP WT) derived from the same intermediate virus
were isolated as described for VACV A41L gene [38]. A revertant virus
with or without an HA tag (v-GAAP Rev and v-GAAP RevHA) were
constructed in a similar manner, using VACV v-DGAAP as parent
virus and plasmids pSJH7-GAAPRev and pSJH7-GAAPRevHA,
respectively. All virus isolates were plaque-puriﬁed three times and
the virus genomes were analysed by Southern blotting and PCR using
DNA extracted from virus cores [39].
Stable cell lines. U2OS cells were transfected with either the
pCDNA3.1- or pCDNA3.1-encoding human or viral GAAPs-HA using
Lipofectamine (Invitrogen); 48 h post-transfection, cells were treated
with 500 lg/ml of G418. After 1 mo, isolated colonies were cloned and
the expression of transfected sequences was determined by immuno-
ﬂuorescence and immunoblotting. Staurosporine- and Fas-induced
apoptosis assays (see apoptosis assay section below) were carried out
with two independent U2OS-v-GAAP clones or three independent
U2OS-h-GAAP clones. Each clone gave similar results to those shown
for the two clones described throughout the paper.
Flow cytometry. Saos-2 cells (106) were seeded in 10-cm diameter
plates; after 24 h, cells were transfected with plasmids expressing
CD20 (2 lg), Bax (5 lg), and 15 lg of pCI or pCI-v-GAAP or pCI-h-
GAAP-HA as indicated. Then, 36 h after transfection, both attached
and ﬂoating cells were harvested and analyzed as described [40].
Apoptosis assays. Cells were seeded into 6-well dishes at 4–63 105
cells/well. One day later, cells were treated with 3 lM staurosporine, 10
mg/ml cisplatin, 500 ng/ml anti-Fas Ab (Clone CH11; Upstate
Biotechnology, http://www.upstate.com), or 10 ng/ml of human TNF-
a (PeproTech EC, http://www.peprotechec.com). Fas and TNF-a were
used in combination with 10 lg/ml of CHX (Sigma). For induction of
apoptosis by C2-ceramide (N-acetyl-D-sphingosine, Sigma), cells were
preincubated in modiﬁed KRB buffer (125 mMNaCl, 5 mMKCl, 1 mM
MgSO4, 1 mM Na2HPO4, 5.5 mM glucose, 20 mM NaHCO3, 2 mM L-
glutamine, and 20 mM HEPES [pH7.4]) supplemented with 1 mM
CaCl2 for 4 h and treated with 10 lM C2-ceramide in the same
medium. At the indicated time post all treatments, both attached and
ﬂoating cells were harvested using 4 mMEDTA/PBS. The DNA content
of all the cells was analyzed using ﬂow cytometry as described above.
Immunoﬂuorescence. HeLa, U2OS-neo, U2OS-v-GAAP, or U2OS-
h-GAAP cells were grown on coverslips, and intracellular proteins
were stained as described [41]. For detection of endogenous h-GAAP,
cells were ﬁxed with 3% PFA in PBS on ice for 20 min, and
permeabilised and stained as above. For detection of v-GAAP after
VACV infection, HeLa cells were infected at 10 pfu/cell and ﬁxed as
above 4 h p.i. Samples were examined with a Zeiss LSM 510 laser
scanning confocal microscope. Images were captured and processed
using Zeiss LSM Image Browser version 3.1.0.99 (http://www.zeiss.
com). Primary antibodies used were mouse a-HA mAb (1:1000;
Covance, http://www.covance.com), rat high afﬁnity a-HA mAb (clone
3F10, 1:1000; Roche, http://www.roche.com), rabbit a-GAAP (1:50),
mouse a-GM130 (1:100, BD Transduction Laboratories; BD Bioscien-
ces, http://www.bdbiosciences), or mouse a-A36R mAb (1:100, [42]).
Electron microscopy. For conventional electron microscopy and
for cryo-immunocytochemistry, cells were treated as described [43].
All images were acquired on a FEI Tecnai G2 electron microscope
(http://www.fei.com) using a MegaView III CCD camera (Olympus Soft
Imaging Solutions, http://www.soft-imaging.net) operating under
analySIS Docu software.
Immunoblotting. Cells were lysed in RIPA or LDL buffer and
between 50 and 200 lg of protein was analyzed by immunoblotting as
described [41]. Primary antibodies used were rabbit a-GAAP (1:200),
mouse a-HA mAb (1:1000; Covance), rat a-alpha tubulin (YL1/2,
1:2000; Serotec, http://www.ab-direct.com), and mouse a-cleaved
PARP (Asp214) mAb (1:1000, 19F4; Cell Signaling Technology,
http://www.cellsignal.com).
RNAi transfection. siRNA sequences speciﬁc to h-GAAP were
designed using ‘‘siDIRECT’’ [44,45] and were from Ambion (http://
www.ambion.com). GAAP siRNA1: 59- CGAUCGAGGACGACUUCAA-
CU-39 (sense) and 59- UUGAAGUCGUCCUCGAUCGAG-39 (anti-
sense); GAAP siRNA2: 59- CUGUACGGACAUUUGUACAUG-39
(sense) and 59- UGUACAAAUGUCCGUACAGAC-39 (antisense);
GAAP siRNA3: 59- CGGAUCUCUGGGUUUGAUUUU-39 (sense) and
59- AAUCAAACCCAGAGAUCCGAG-39 (antisense). As a control,
siRNA to GFP (Dharmacon, http://www.dharmacon.com) was used.
Cells were grown to 50% conﬂuency in 6-well plates and transfected
with 1 lg of siRNAs using siFECTamine (IC-Vec,UnitedKingdom) [46].
The transfection efﬁciency was determined to be .97% using
siFECTamine labeled with Dioleoyl-sn-Glycero-3-Phosphoethanol-
amine-N-(Lissamine-Rhodamine-B-Sulfonyl) (IC-Vec) by ﬂow cytom-
etry and immunoﬂuorescence analysis (unpublished data).
Semi-quantitative RT-PCR. For semi-quantitative RT-PCR after
siRNA transfection, total RNA was extracted from HeLa cells using
TRIzol reagent (Invitrogen) and treated with Ampliﬁcation grade
DNAseI (Invitrogen) before semi-quantitative RT-PCR analysis was
performed using the SuperScriptTM III One-Step RT-PCR System
(Invitrogen). Each reaction contained 0.2 lg of total RNA and
the optimal number of cycles for linear ampliﬁcation for
tissue expression analysis. Primers were h-GAAP forward: 59-
GCCCCGAATTCTGCCATCATGGCTGACCCCG-39 and reverse: 59-
GCCCCTCGAGTTACTTTTTATTAACTGCTTCCAGAAACC-39; and
actin forward: 59-GTGGGGCGCCCCAGGCACCA-39 and reverse 59-
CTCCTTAATGTCACGCACGATTTC-39.
To determine the time of expression of VACV GAAP during
infection, TK143 cells were infected with 5 pfu/cell of CMLV with or
without 40 lg/ml AraC. After 2, 5, or 22 h, total RNA was extracted
from cells using the RNEasy Midi kit (Qiagen, http://www.qiagen.com)
treated with Ampliﬁcation Grade DNAseI (Invitrogen). Semi-qunti-
tative RT-PCR analysis was performed as above. Primers were v-
GAAP exp1, v-GAAP exp2, D8L-1 (59-GTCTCTCTCAAATCGGAC),
and D8L-2 (59-GCAAAAAAAACACGATGA).
Mitochondrial membrane potential. Mitochondrial membrane po-
tential was quantiﬁed by staining with TMRE (Molecular Probes, http://
probes.invitrogen.com). Cells were loaded with TMRE by incubating cells
in medium containing 0.2 lM TMRE for 30 min at 37 8C. TMRE
ﬂuorescencewasacquiredusingﬂowcytometry throughtheFL-2channel.
Virulence assays of v-GAAP mutant viruses in mice. For intranasal
infections, groups of BALB/c mice (6–8 wk old) were inoculated under
general anaesthesia with virus in 20 ll PBS. Each day, mice were
weighed individually and monitored for signs of illness [27], and those
suffering a severe infection or having lost 30% of their original body
weight were sacriﬁced. To obtain BAL ﬂuid, mice were killed and their
lungs were inﬂated ﬁve times with 1.5 ml of 12 mM lidocaine and 5mM
EDTA in Earle’s Balanced Salt Solution (Sigma) through a blunted 23-
gauge needle inserted into the trachea. BAL ﬂuids were centrifuged
(2,000 rpm, 10 min) and the cells were re-suspended in erythrocyte
lysis buffer (0.829% NH4Cl, 0.1% KHCO3, 0.0372% Na2EDTA, [pH
7.2]) for 5 min at RT. Cells were washed with RPMI 1640 medium
(Gibco) and cell viability was assessed using trypan blue exclusion.
Statistical analysis. The Student’s t-test (two-tailed) was used to test
the signiﬁcance of the results.
Supporting Information
Figure S1. Protein Trafﬁcking to the Cell Surface Is Not Affected by
GAAPs
U2OS-neo, U2OS-v-GAAP, or U2OS-h-GAAP cells were transfected
with a plasmid encoding vesicular stomatitis virus glycoprotein G
fused to GFP and were ﬁxed for analysis by ﬂuorescence microscopy
4, 7, and 24 h post transfection.
Scale bars, 20 lm.
Found at doi:10.1371/journal.ppat.0030017.sg001 (584 KB PPT).
Figure S2. Down-Regulation of Human GAAP Induces Loss of
Mitochondrial Membrane Potential
HeLa cells, mock-transfected or transfected with h-GAAP siRNAs 1–3
for 56 h, were loaded with the mitochondrial membrane potential
sensor TMRE. Loss of mitochondrial membrane potential was
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measured as a decrease in TMRE ﬂuorescence by two-color ﬂow
cytometry (cell population labeled M1).
Found at doi:10.1371/journal.ppat.0030017.sg002 (76 KB PPT).
Accession Numbers
The Genbank (http://www.ncbi.nlm.nih.gov/Genbank) accession num-
bers for the proteins discussed in this paper are A. thaliana GAAP
(NP_193209), CMLV strain CM-S GAAP (AAG37461), dog GAAP
(XP531662), D. melanogaster GAAP (Q9V6H6); h-GAAP (CGI-119,
AAD34114; S1R protein, AAF14868; and z-protein, AF182041), mouse
GAAP (Q9DA39), orangutan GAAP (Q5R8M0), VACV Evans GAAP
(AY690669), VACV Lister GAAP (AY699305), VACV USSR GAAP
(AY699306),X. laevisGAAP(AAH90219), andzebraﬁshGAAP(Q5TZH2).
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